As Advair Sales Fall, GSK’s Witty Reminds Investors Launches Need Time
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s sales of Advair nose-dived 15% in the first quarter due to pricing pressure and loss of insurance coverage. New respiratory products like Breo Ellipta have yet to make a dent toward shoring up respiratory sales.
You may also be interested in...
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.